The study was funded by several NIH components, primarily the National Institute of Allergy and Infectious Diseases (NIAID).
PJ Utz at Stanford University, Chrysanthi Skevaki at Philipps University Marburg in Germany, and Eline Luning Prak at the University of Pennsylvania. To look at this question, researchers screened for a range of autoantibodies in blood samples from almost 150 people hospitalized with COVID-19 and 41 healthy volunteers. Scientists have wondered if infection with SARS-CoV-2 could also result in the production of autoantibodies in people who didn’t have them before they got sick. Many people with low levels of autoantibodies in their blood have no obvious symptoms.Ī recent study found that autoantibodies that existed before infection with SARS-CoV-2 may account for 20% or more of serious or fatal COVID-19 cases. Autoantibodies are found in a wide range of autoimmune diseases, such as lupus and rheumatoid arthritis. Autoantibodies-immune system proteins that mistakenly target the body’s own tissues-may underlie some of this variation. Researchers are beginning to understand how the human immune system contributes to the varied responses to COVID-19. Others experience so-called “long COVID,” symptoms that persist long past recovery from the initial stages of illness.
Some people have a severe or fatal reaction to infection, while others show no obvious symptoms. More than a year and a half into the COVID-19 pandemic, much about how the human body responds to SARS-CoV-2, the virus that causes COVID-19, remains unclear. Colorized scanning electron micrograph of a cell (red) infected with a variant strain of SARS-CoV-2 virus particles (green), isolated from a patient sample.
0 kommentar(er)
